Shigeki Yoshida

Shigeki Yoshida

Auto-generated profile, based on publicly available information

Shigeki Yoshida

Faculty of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1994 in Bioscience, Biotechnology, and Biochemistry
Verified
Journal Article
Closed access
SKSatoshi Kitao
Satoshi Kitao
SYShigeki Yoshida
Shigeki Yoshida
THTatsuo Horiuchi
Tatsuo Horiuchi
HSHiroshi Sekine
Hiroshi Sekine
IKIsao Kusakabe
Isao Kusakabe

1 October 2008 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
KTK. Takeuchi
K. Takeuchi
TTTakuya Tsujino
Takuya Tsujino
MSM. Sugimoto
M. Sugimoto
SYS. Yoshida
S. Yoshida
SKS. Kitazawaz
S. Kitazawaz

1 January 2017 in Food Science and Technology Research
Verified
Journal Article
Open access
PDF file
JSJi-Hyun Song
Ji-Hyun Song
HMHitoshi Miyazaki
Hitoshi Miyazaki
SYShigeki Yoshida
Shigeki Yoshida
Methods for the production and isolation of the tea components teadenols A and B were developed because of their potential anti-metabolic syndrome activity. Aspergillus sp. (FARM AP-21280) was inoculated to a modified Czapek-Dox medium containing (-)-epigallocatechin 3-O-gallate (EGCG) and (-)-gallocatechin 3-O-gallate (GCG) and incubated at 25°C. The maximum contents of the teadenols were observed at 19 days, and the contents increased depending on the initial EGCG concentration. The addition of green tea powder to the medium enhanced the production of teadenols. In the modified Czapek-Dox medium containing 5.0% EGCG and 1.0% green tea powder, teadenols A and B were efficiently produced at 3.22 ± 0.23 and 4.49 ± 0.38 mg/mL, respectively. The teadenols were purified by sequential chromatography on Sephadex LH-20 and InertSustain™ C18 columns. After purification by preparative HPLC, 0.27 g teadenol A (29.7% recovery) and 0.45 g teadenol B (42.9% recovery) were obtained from the 970 mL culture filtrate.

14 June 2023 in Molecular & Cellular Toxicology
Verified
Journal Article
Closed access
PDF file
WLWonJune Lee
WonJune Lee
TTTomoko Terada
Tomoko Terada
WJWenQian Jiang
WenQian Jiang
YZYiQian Zhang
YiQian Zhang
HMHitoshi Miyazaki
Hitoshi Miyazaki
SYShigeki Yoshida
Shigeki Yoshida

7 September 2022 in Research Square
Verified
Preprint
Open access
PDF file
JLJicHyun Lee
JicHyun Lee
TTTomoko Terada
Tomoko Terada
WJWenQian Jiang
WenQian Jiang
HMHitoshi Miyazaki
Hitoshi Miyazaki
SYShigeki Yoshida
Shigeki Yoshida
The present study compared the effects of green tea (–)-epigallocatechin gallate (EGCG) and black tea theaflavin on vascular endothelial cell (VEC) function via the gasotransmitters, hydrogen sulfide (H2S) and nitric oxide (NO). The reaction conditions for cell-free extracts of VECs and L-cysteine were optimized to detect H2S, which was measured using monobromobimane (MBB). EGCG and theaflavin were applied to VECs at 10 µM, and H2S and NO were measured using the MBB method and a NO-specific probe, diaminofluorescein-2 diacetate, respectively. The effects on the functions of VECs were evaluated based on wound healing and cell viability. Theaflavin significantly stimulated H2S production in VECs by 1.51-fold compared to the control, but EGCG showed no effect. In contrast, EGCG and theaflavin increased NO production (1.63 and 2.16-fold), wound healing (1.30- and 1.75-fold), and cell viability (85.0 and 90.0%). The potency of theaflavin was found to be higher than that of EGCG. By inhibiting cystathionine-γ-lyase activity with 100 µM of DL-propargylglycine (PPG) treatment, all cell responses were suppressed in both EGCG and theaflavin treatments, and the reduction rate in the case of theaflavin treatment was higher than that of the control and EGCG treatments in all responses. These results indicate that the protective effect of VECs is dependent on NO production, and that both EGCG and theaflavin have therapeutic potential in VECs. Theaflavin has a relatively higher therapeutic potential than EGCG by increasing H2S production, thereby affecting NO production and biological activity.